122 results
10-K
2023 FY
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
on the development of innovative therapeutics for rare diseases. We have developed a portfolio of late-stage clinical product candidates. Our two rare disease … infrastructure to commercialize the products in key markets.
Our Strategy
We intend to become a leading biopharmaceutical company developing innovative
8-K
EX-99.1
MREO
Mereo Biopharma Group Plc
27 Mar 24
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
4:08pm
shares of the Company.
About Mereo BioPharma
Mereo BioPharma is a biopharmaceutical company focused on the development of innovative therapeutics
8-K
EX-99.1
MREO
Mereo Biopharma Group Plc
8 Jan 24
Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments
7:08am
of innovative therapeutics for rare diseases. The Company has two rare disease product candidates, setrusumab for the treatment of Osteogenesis Imperfecta
6-K
EX-99.1
MREO
Mereo Biopharma Group Plc
23 Oct 23
Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update
4:08pm
on the development of innovative therapeutics for rare diseases. The Company has two rare disease product candidates, setrusumab for the treatment
6-K
EX-99.1
MREO
Mereo Biopharma Group Plc
17 Oct 23
Current report (foreign)
7:01am
on the development of innovative therapeutics for rare diseases. The Company has two rare disease product candidates, setrusumab for the treatment
6-K
EX-99.1
2sk 7vrb4qx1sk3c3
7 Sep 23
Current report (foreign)
7:37am
6-K
EX-99.3
e6crhpwhtt0qzw6dgwd9
7 Sep 23
Current report (foreign)
7:37am
6-K
EX-99.2
tlhjn3vrn 2r5939tzdn
7 Sep 23
Current report (foreign)
7:37am
6-K
EX-99.1
rd55pe
5 Jun 23
Ultragenyx and Mereo BioPharma Announce Positive Data from the Ongoing Phase 2/3 Orbit
4:37pm
6-K
EX-99.1
49fjmkwgiy30e3qs
8 May 23
Current report (foreign)
4:07pm
6-K
EX-99.1
y7z2h78mdnrg46m2vz
5 May 23
Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market
5:06pm
6-K
EX-99.2
bywtt6a2ikqkl
2 Nov 22
Current report (foreign)
4:17pm
6-K
EX-99.1
20nesi6 c3rbw09y3v
2 Nov 22
Current report (foreign)
4:17pm
6-K
EX-99.1
0pt0s001rrppkx1ot4md
2 Nov 22
Mereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency
4:07pm
6-K
EX-99.1
q9rb5f pu8xuvcn
28 Oct 22
Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management
7:11am
6-K
EX-99.1
eq5 a5ho1n
21 Oct 22
Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting
7:06am
6-K
EX-99.1
cag5b4ee1
18 Oct 22
Mereo BioPharma Announces Updated Operating Plan to Maximize Shareholder Value
7:07am
6-K
EX-99.1
dn8rm3lt2pb1g
17 Oct 22
Mereo BioPharma Receives FDA Fast Track Designation for Alvelestat for Treatment of
7:16am
6-K
EX-99.1
qkgvarunfawd6
3 Oct 22
Mereo BioPharma Confirms Receipt of a Valid Notice Requiring it to Convene a General Meeting of Shareholders
5:43pm
6-K
EX-99.1
vo5sy4nc4oy5yspeqcz
26 Sep 22
Mereo BioPharma Offered to Settle Proxy Contest with Rubric Capital Management by
7:18am